By Denny Jacob
Incyte and Novartis Pharma reached a settlement related to litigation initiated by the latter company regarding royalty payments.
Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty rate payable by the company to Novartis on future sales of Jakafi in the U.S. beginning Jan. 1, 2025.
Incyte said the difference of $242.2 million between the total accrued royalties and the total amount it will pay to Novartis will be recorded in its financial statements for the quarter ending June 30.
Incyte and Novartis entered into a collaboration and license agreement in 2009.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 14, 2025 08:30 ET (12:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。